Skip to main content
Top
Published in: Diabetologia 3/2019

01-03-2019 | Article

Maternal metabolites during pregnancy are associated with newborn outcomes and hyperinsulinaemia across ancestries

Authors: Rachel Kadakia, Michael Nodzenski, Octavious Talbot, Alan Kuang, James R. Bain, Michael J. Muehlbauer, Robert D. Stevens, Olga R. Ilkayeva, Sara K. O’Neal, Lynn P. Lowe, Boyd E. Metzger, Christopher B. Newgard, Denise M. Scholtens, William L. Lowe Jr, for the HAPO Study Cooperative Research Group

Published in: Diabetologia | Issue 3/2019

Login to get access

Abstract

Aims/hypothesis

We aimed to determine the association of maternal metabolites with newborn adiposity and hyperinsulinaemia in a multi-ethnic cohort of mother–newborn dyads.

Methods

Targeted and non-targeted metabolomics assays were performed on fasting and 1 h serum samples from a total of 1600 mothers in four ancestry groups (Northern European, Afro-Caribbean, Mexican American and Thai) who participated in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, underwent an OGTT at ~28 weeks gestation and whose newborns had anthropometric measurements at birth.

Results

In this observational study, meta-analyses demonstrated significant associations of maternal fasting and 1 h metabolites with birthweight, cord C-peptide and/or sum of skinfolds across ancestry groups. In particular, maternal fasting triacylglycerols were associated with newborn sum of skinfolds. At 1 h, several amino acids, fatty acids and lipid metabolites were associated with one or more newborn outcomes. Network analyses revealed clusters of fasting acylcarnitines, amino acids, lipids and fatty acid metabolites associated with cord C-peptide and sum of skinfolds, with the addition of branched-chain and aromatic amino acids at 1 h.

Conclusions/interpretation

The maternal metabolome during pregnancy is associated with newborn outcomes. Maternal levels of amino acids, acylcarnitines, lipids and fatty acids and their metabolites during pregnancy relate to fetal growth, adiposity and cord C-peptide, independent of maternal BMI and blood glucose levels.
Appendix
Available only for authorised users
Literature
11.
go back to reference HAPO Study Cooperative Research Group (2008) Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358:1991–2002CrossRef HAPO Study Cooperative Research Group (2008) Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358:1991–2002CrossRef
34.
Metadata
Title
Maternal metabolites during pregnancy are associated with newborn outcomes and hyperinsulinaemia across ancestries
Authors
Rachel Kadakia
Michael Nodzenski
Octavious Talbot
Alan Kuang
James R. Bain
Michael J. Muehlbauer
Robert D. Stevens
Olga R. Ilkayeva
Sara K. O’Neal
Lynn P. Lowe
Boyd E. Metzger
Christopher B. Newgard
Denise M. Scholtens
William L. Lowe Jr
for the HAPO Study Cooperative Research Group
Publication date
01-03-2019
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 3/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-018-4781-1

Other articles of this Issue 3/2019

Diabetologia 3/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.